

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

ELITE PHARMACEUTICALS INC /DE/  
Form 3  
January 06, 2003

-----  
OMB APPROVAL  
-----  
OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden  
hours per response.....0.5  
-----

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 3

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or  
Section 30(h) of the Investment Company Act of 1940

(Print of Type Responses)

---

1. Name and Address of Reporting Person\*

Moore	John	A
-----	-----	-----
(Last)	(First)	(Middle)

c/o Edson Moore Corp.  
1011 Brookmeadow Road

---

(Street)

Wilmington	Delaware	19807
-----	-----	-----
(City)	(State)	(Zip)

---

2. Date of Event Requiring Statement (Month/Day/Year)

12/12/2002

---

3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)

---

4. Issuer Name and Ticker or Trading Symbol

Elite Pharmaceuticals, Inc. - AMEX: ELI

---

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)

<input checked="" type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
<input type="checkbox"/> Officer (give title below)	<input type="checkbox"/> Other (specify below)

---

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

6. If Amendment, Date of Original (Month/Day/Year)

7. Individual or Joint/Group Filing (Check Applicable line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I -- Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature (Instr.)
Common Stock, par value \$0.01 per share ("Common Stock")	764,218	I	By Eds corpor

FORM 3 (continued)

Table II -- Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

3. Title and Amount of Securities  
Underlying Derivative Security

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		(Instr. 4)	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security
	Date Exercisable	Expiration Date	Title		
Warrant to purchase up to 100,000 shares of Common Stock	10-17-2000	10-17-2005	Common Stock	100,000	\$18.00

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Explanation of Responses:

/s/ John A. Moore	12-16-2002
-----	-----
**Signature of Reporting Person	Date

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.